The invention claimed is:

1. A complex of agomelatine and sulphonic acids of formula (I):



(I)

,

wherein x represents 0 or 1, and RSO_3H represents 1,5-naphthalenedisulphonic acid or benzenesulphonic acid.

2. The agomelatine complex according to claim 1, which is the agomelatine / 1,5-naphthlenedisulphonic acid (2/1) complex.

3. The agomelatine complex according to claim 2, having the following X-ray powder diffraction diagram expressed in terms of interplanar distance d, Bragg's angle 2 theta (expressed in °±0.2), and relative intensity, as follows:

2-Theta (°) exp.	d (Å) exp.	Intensity (%)
6.3716	13.87229	18.97
11.3804	7.77552	17.98
11.9227	7.42299	36.06
12.5064	7.07784	100.00
12.6590	6.99288	13.75
14.5508	6.08767	44.17
15.5658	5.69292	11.96
16.2029	5.47051	42.63
16.9421	5.23346	25.85
17.6267	5.03171	18.67
19.4300	4.56857	49.04
20.2146	4.39301	22.77

21.4353	4.14550	17.80
21.6713	4.10090	22.84
22.2180	4.00121	64.19
22.4174	3.96607	10.83
24.0749	3.69664	29.61
24.5048	3.63275	13.33
25.1744	3.53763	20.58
25.7599	3.45853	23.59

including the forms whose diffraction angles correspond to within ±0.2°.

4. The agomelatine complex according to claim 1, which is the agomelatine / 1,5-naphthlenedisulphonic acid (2/1) monohydrate complex.

5. The agomelatine complex according to claim 4, having the following X-ray powder diffraction diagram expressed in terms of interplanar distance d, Bragg's angle 2 theta (expressed in °±0.2), and relative intensity, as follows:

2-Theta (°) exp.	d (Å) exp.	Intensity (%)
9.6680	9.14852	12.45
12.4885	7.08796	57.23
12.6164	7.01639	28.61
14.5042	6.10715	57.42
16.2684	5.44863	25.67
16.4624	5.38484	32.93
16.8967	5.24739	90.90
19.3772	4.58091	10.50
22.4767	3.95573	100.00
23.4111	3.79992	20.49
23.5330	3.78051	44.02
23.6735	3.75840	21.92
24.0477	3.70076	13.67
24.5716	3.62303	13.43

25.1240	3.54460	12.46
26.6602	3.34374	19.10
28.1333	3.16930	12.07
28.2443	3.15971	22.49

including the forms whose diffraction angles correspond to within ±0.2°.

6. The agomelatine complex according to claim 1, which is the agomelatine / benzenesulphonic acid (2/1) complex.

7. The agomelatine complex according to claim 6, having the following X-ray powder diffraction diagram expressed in terms of interplanar distance d, Bragg's angle 2 theta (expressed in °±0.2), and relative intensity, as follows:

2-Theta (°) exp.	d (Å) exp.	Intensity (%)
8.0711	10.95469	35.25
12.6820	6.98026	68.37
12.7706	6.93203	65.37
13.0114	6.80427	15.18
13.3054	6.65458	31.84
14.9475	5.92700	19.42
15.1121	5.86283	70.19
15.4873	5.72160	14.16
16.1644	5.48344	12.98
17.2360	5.14486	21.06
18.1046	4.89993	36.33
18.6255	4.76406	10.91
18.8009	4.72001	33.43
20.0908	4.41978	30.26
20.4742	4.33788	42.37
20.6921	4.29270	56.78
20.8640	4.25771	26.42

21.7142	4.09289	13.88
23.3683	3.80679	15.16
23.6410	3.76349	100.00
24.9314	3.57154	26.81
25.6543	3.47253	10.71
27.5599	3.23660	14.00

including the forms whose diffraction angles correspond to within ±0.2°.

8. A process for obtaining the complex of agomelatine and sulphonic acids according to claim 1, wherein:

- the agomelatine and sulphonic acids are mixed in an organic or aqueous hydro-organic solvent in the desired proportions;
- the solution obtained is stirred and optionally heated at a temperature not greater than the boiling point of the chosen solvent;
- the mixture is cooled, with stirring, and the co-crystal precipitates naturally or precipitates after being taken up in a second solvent;
- the precipitate obtained is filtered off and dried.

9. A process for the preparation of the complex of agomelatine and sulphonic acids according to claim 1, wherein the two constituents are co-ground.

10. A process for the preparation of the complex of agomelatine and sulphonic acids according to claim 1, wherein the two constituents are mixed in an organic or aqueous-organic solvent and are then frozen and dried at very low temperature.

11. A process for the preparation of the complex of agomelatine and sulphonic acids according to claim 1, wherein the powders of agomelatine and the acid in question are mixed in a mixer and then the mixture is extruded by means of twin-screw extrusion without a die in order to obtain a solid grain directly at the outlet of the extruder.

12. A pharmaceutical compositions comprising as active ingredient the complex of agomelatine and sulphonic acids according to claim 1, in combination with one or more inert, non-toxic, pharmaceutically acceptable carriers.

13. A method of treating disorders of the melatoninergic system comprising administering to a subject in need thereof a complex of agomelatine and sulphonic acids according to claim 1, alone or in combination with one or more inert, non-toxic, and pharmaceutically acceptable carriers.

14. A method of treating a condition selected from stress, sleep disorders, anxiety disorders and especially generalised anxiety disorder, obsessive compulsive disorders, mood disorders and especially bipolar disorders, major depression, seasonal affective disorder, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jet-lag, schizophrenia, panic attacks, melancholia, appetite disorders, obesity, insomnia, pain, psychotic disorders, epilepsy, diabetes, Parkinson's disease, senile dementia, disorders associated with normal or pathological ageing, migraine, conditions requiring an ovulation inhibitor and conditions requiring an immunomodulator in a subject in need thereof, comprising administration of the complex of agomelatine and sulphonic acids according to claim 1, alone or in combination with one or more inert, non-toxic, and pharmaceutically acceptable carriers.